Clinical trials located in

Oxford

Oxford city is located in United Kingdom. Currently, 20 clinical trials are being conducted in this city.

Oxford, a historic city in the United Kingdom, is renowned for its prestigious University of Oxford, the oldest university in the English-speaking world, dating back to the 12th century. This city of dreaming spires, a term coined by poet Matthew Arnold, is distinguished by its medieval architecture, including the iconic Radcliffe Camera and the Bodleian Library. Oxford has also been a backdrop for numerous films and books, notably inspiring Lewis Carroll’s “Alice in Wonderland” and serving as a filming location for the Harry Potter series.

  • CT-EU-00068643

    Study of the effects and safety of Inavolisib and Fulvestrant compared with Alpelisib and Fulvestrant in patients with advanced breast cancer

    The clinical trial is for breast cancer. Its aim is to evaluate the effectiveness and safety of the drug combination inavolisib and fulvestrant compared with the drug combination alpelisib and fulvestrant.

    It is aimed at patients with locally advanced or metastatic breast cancer. All patients who will participate in the study have previously undergone therapy based on cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors and hormonal therapy. Study participants’ breast cancer must be hormone receptor positive (HR+), human epidermal growth factor receptor type 2 negative (HER2-), and must have a PIK3CA gene mutation.

    The aim of the study is to compare which drug combination – inavolisib and fulvestrant or alpelisib and fulvestrant – is more effective in the treatment of this type of breast cancer. This study also tries to assess what the side effects of both therapies are.

    Inavolisib and fulvestrant treatment involves administering inavolisib tablets once a day and fulvestrant injections at the beginning and during treatment cycles. An alternative treatment, i.e. alpelisib with fulvestrant, also involves daily use of alpelisib tablets and fulvestrant injections according to planned cycles.

    • Alpelisib
    • Fulvestrant
    • Inavolisib
  • Study of INBRX-109 for patients with unresectable or metastatic conventional chondrosarcoma

    Conventional chondrosarcoma is a type of cancer that affects the bones. This clinical trial focuses on evaluating a new treatment for patients with unresectable (inoperable) or metastatic (spread to other parts of the body) conventional chondrosarcoma. The therapy being tested is called INBRX-109. INBRX-109 is an experimental drug, specifically a humanized antibody that targets a protein called death receptor 5 (DR5). The study aims to determine whether INBRX-109 can help patients who have this type of bone cancer.

    In this study, participants will be randomly assigned to one of two groups: one group will receive INBRX-109, and the other will receive a placebo. Neither the participants nor the researchers will know who is receiving the actual drug and who is receiving the placebo. This is known as a double-blind study. Participants will receive their assigned treatment through an intravenous infusion every three weeks. If the disease progresses, those in the placebo group will be allowed to switch to the INBRX-109 treatment.

    The primary goal of the study is to see how well INBRX-109 works in preventing the cancer from getting worse. The study will also look at overall survival rates, how long any responses to the treatment last, and the quality of life of the participants during the study. Safety and tolerability of INBRX-109 will also be evaluated by monitoring for any side effects. Participants will have regular visits and tests to check on their condition and the effects of the treatment. This clinical trial offers a potential new treatment option for patients with difficult-to-treat chondrosarcoma, aiming to improve their outcomes and quality of life.

    • INBRX-109
    • placebo
  • Study on the effectiveness and safety of M281 in adults with warm Autoimmune Hemolytic Anemia

    The study focuses on Warm Autoimmune Hemolytic Anemia (wAIHA), a condition where the immune system mistakenly destroys red blood cells. This leads to symptoms like fatigue, weakness, and jaundice (yellowing of the skin or eyes). The trial examines the effects of a therapy named M281 (Nipocalimab). The purpose of the study is to evaluate the efficacy and safety of M281. Patients participating in the study will receive either M281 or a placebo. It aims to compare improvements in health and monitor any side effects.

    The study structure is as follows:

    Double-blind period: This lasts for 24 weeks, where participants will be randomly assigned to one of three groups. One group will receive M281 every 4 weeks, alternating with a placebo every 4 weeks. Another group will receive M281 every 2 weeks, and the third group will receive a placebo every 2 weeks.

    Open-label extension period: This phase extends for 144 weeks, where all participants will receive M281, either every 2 weeks or every 4 weeks.

    Participants will be monitored for 8 weeks after the last dose to check for any ongoing effects of the treatment. The study aims to provide comprehensive information about the effectiveness and safety of M281 in treating wAIHA.

    • M281
    • placebo
  • Testing Vemurafenib and Cobimetinib for BRAF Positive Cancers

    This clinical trial is for patients with cancers that have a specific change in their cancer cells known as BRAF V600 mutation. It uses two drugs, vemurafenib and cobimetinib, to see if they can effectively treat various types of cancers such as solid tumors, haematological malignancies, melanoma, thyroid cancer, ovarian neoplasms, colorectal neoplasms, laryngeal neoplasms, non-small-cell lung carcinoma, glioma, multiple myeloma, and Erdheim-Chester disease. The purpose of this study is to determine if these drugs can help treat cancers with the BRAF V600 mutation.

    In the study, participants will receive both drugs until their disease progresses, they experience unacceptable side effects, or they decide to withdraw. Blood samples will be collected at different times during the treatment for research purposes. Participants will be monitored every three months for two years after completing the treatment.

    • Vemurafenib
    • Cobimetinib
  • Baricitinib study in children with juvenile idiopathic arthritis

    This clinical trial is designed to test whether Baricitinib is safe and effective in the treatment of systemic juvenile idiopathic arthritis in children aged 1 to 18 years. Participants will be assigned to one of two groups. In the first group, some participants will receive Baricitinib and others Tocilizumab as the reference drug. In the second group, all participants will receive Baricitinib.

    The primary objective of the study is to evaluate the percentage of participants who experience at least a 30% improvement in disease symptoms after 12 weeks of treatment according to the modified American College of Rheumatology Pediatric Response Criteria (PediACR30). Baricitinib is administered orally and Tocilizumab is administered by subcutaneous injection.

    • Tocilizumab
    • baricitinib
  • A study on the use of the new drug NX-1607 for patients with advanced types of various cancers

    The main goal of this study is to test the safety and effectiveness of a new drug called NX-1607 in the treatment of various types of advanced cancers. NX-1607 is taken orally and works by blocking a protein called Cbl-b.

    The study consists of two parts. The first part, called Phase 1a, will study different doses of NX-1607 alone or in combination with paclitaxel to find the highest safe dose. This section includes patients with cancers such as ovarian, stomach, head and neck, melanoma, lung, prostate, mesothelioma, breast, bladder, cervical, colorectal and lymphoma.

    In the second part, called Phase 1b, selected doses from Phase 1a will be administered to separate groups of patients with the same type of cancer. The main goal is to see if NX-1607, alone or with paclitaxel, can shrink or control tumors. Patient safety will be continuously monitored by researchers.

    The goal of this study is to find the right dose of the experimental drug NX-1607 and see if it has promising anti-cancer effects in a variety of advanced cancers for which treatment options are limited. Patient safety is the highest priority throughout the entire examination.

    • NX-1607
    • Paclitaxel
  • Study of a new anticancer vaccine (SCIB1) in combination with immunotherapeutic drugs in the treatment of malignant melanoma

    The aim of this clinical trial is to test whether a new cancer vaccine called SCIB1 can be safely used with two approved treatments for advanced melanoma – nivolumab (Opdivo) plus ipilimumab (Yervoy) or pembrolizumab (Keytruda). The study will also examine whether adding SCIB1 to these therapies can increase the chances of melanoma responding to treatment and the duration of that response.

    Currently, SCIB1 is still considered experimental, but has been previously administered to melanoma patients and was well tolerated. Scientists have even seen some signs that it may help stimulate the immune system to fight cancer. In this study, SCIB1 will be administered up to 10 times over 85 weeks by injection into the arm or leg using a special needle-free device. Before starting treatment, you will undergo several screening tests to make sure you are eligible to take part.

    • SCIB1 DNA vaccine
  • Tebentafusp for the treatment of recurrent melanoma

    The study aims to investigate a new treatment for patients with cutaneous melanoma or uveal melanoma after surgery. Researchers want to see if a new drug called tebentafusp can help these patients live longer.

    Tebentafusp is a new drug that has already been studied in patients with advanced melanoma of the skin and uvea. In this study, this medicine will be administered to patients whose disease has relapsed at the molecular level using a special blood test. Patients will receive tebentafusp for up to 6 months as an intravenous infusion once a week and will then be followed for 12 months to check whether the disease has returned.

    • tebentafusp
  • Study of the drug combination mRNA-4157/V940 and Pembrolizumab in the treatment of melanoma

    The aim of this clinical trial is to test whether a new drug called mRNA-4157/V940 in combination with pembrolizumab can help prevent the recurrence of melanoma in people who have already had it. Currently, mRNA-4157/V940 is what is called “individualized neoantigen therapy,” which means it is a therapy created specifically for each patient based on their cancer cells. Doctors give this drug along with pembrolizumab, a drug that helps the immune system fight cancer cells.

    The main goal of this study is to determine whether taking V940 and pembrolizumab together is more effective in preventing melanoma recurrence than taking pembrolizumab alone. Researchers will closely monitor how long it takes for the cancer to return or spread. The study will last for approximately 74 months.

    • mRNA-4157/V940
    • placebo
    • Pembrolizumab
  • Comparing ruxolitinib, hydroxycarbamide, and Interferon as first-line treatments for high-risk Polycythemia Vera

    The study, known as MITHRIDATE, investigates the effectiveness of the drug Ruxolitinib compared to either Hydroxycarbamide or Interferon Alpha for patients with high-risk Polycythemia Vera, a type of blood disorder. This Phase III clinical trial aims to determine which treatment is more effective in managing the disease without leading to additional health complications.

    Patients in the trial are assigned to receive either Ruxolitinib or the best available therapy, chosen from Hydroxycarbamide or Interferon Alpha, as decided by the overseeing doctors. The course of the study involves regular monitoring and assessments to evaluate the impact of these treatments on the disease’s progression and patients’ overall health and quality of life. The study is conducted in a controlled environment to ensure reliable results.

    • Interferon-Alpha
    • Hydroxycarbamide
    • Ruxolitinib
  • A study of sapablursen for patients with Polycythemia Vera requiring frequent blood removal

    This study evaluates the drug sapablursen (also known as ISIS 702843 or IONIS-TMPRSS6-LRx) in patients with polycythemia vera, a condition where the body makes too many red blood cells. The main purpose is to see if sapablursen can reduce the need for phlebotomy—a process of drawing blood to lower blood cell count—and improve patients’ quality of life. The study has four phases: screening, initial treatment, extended treatment, and post-treatment, lasting a total of about 96 weeks. Participants will receive sapablursen through subcutaneous injections. There is no placebo involved in this study.

    • sapablursen
  • Study on the Safety and Effectiveness of INCB057643 for Myelofibrosis and Other Myeloid Neoplasms

    This clinical trial is focused on evaluating the safety, tolerability, and initial effectiveness of a medication called INCB057643, either on its own or in combination with another drug known as ruxolitinib. It is designed for participants who are dealing with myelofibrosis or other advanced myeloid neoplasms, which are types of blood disorders. The study aims to understand how well participants can handle the treatment and to observe any potential benefits or side effects that may occur during the trial. The treatment’s impact will be measured by monitoring the number of treatment-related adverse events, which includes any new or worsening symptoms following the start of the medication. This study is an important step towards finding new treatment options for individuals with myelofibrosis and related conditions, offering hope for better management of these diseases.

    • INCB057643
    • Ruxolitinib
  • Exploring a new vaccine regimen with Ipilimumab for myeloproliferative neoplasms

    This clinical trial is focused on evaluating the safety of a new treatment regimen for myeloproliferative neoplasms (MPNs), a type of blood disorder. The treatment involves **VAC85135**, a neoantigen vaccine, which will be given alongside **Ipilimumab**, a medication administered through an IV infusion. The main goal of this study is to understand how safe this combination is for patients with MPNs.

    This study is in its Phase 1, which means it’s the first time this treatment is being tested in people, with the main focus on safety. The trial will start by assessing the participants from the first day of receiving the treatment and will continue to monitor them for up to 79 weeks to capture any potential side effects that may occur.

    • VAC85135
    • Ipilimumab
  • Study on the effectiveness of Givinostat in Non-Walking Duchenne Muscular Dystrophy Patients

    This clinical trial is focused on testing the effectiveness, safety, and how well patients can tolerate a medication called Givinostat for those who have Duchenne Muscular Dystrophy (DMD) and can no longer walk. The study is designed for male pediatric patients aged between 9 to less than 18 years. A total of 138 participants will be involved, and they will be divided into two groups. One group will receive Givinostat, and the other group will receive a placebo, which is a substance with no therapeutic effect, designed to mimic Givinostat. This division will be done randomly and both the patients and the doctors will not know who is receiving the actual medication and who is receiving the placebo, making this a double-blind study.

    The main goal of this study is to see if Givinostat can help reduce muscle decline in patients with DMD who cannot walk, by looking at changes in upper limb function after 18 months of treatment. The safety and tolerability of Givinostat in these patients will also be closely monitored.

    Participants will be involved in the study for about 20 to 21 months, which includes a 4-week screening period to confirm eligibility, 18 months of treatment, and a follow-up period. At the end of the treatment period, all participants, regardless of which group they were in, will have the option to join a long-term safety study where they will receive Givinostat.

    • Givinostat
  • CT-EU-00091440

    Investigating new drug, JNJ-75276617 for the treatment of patients with acute leukemia

    This study is about a new medicine called JNJ-75276617, designed to help patients with a type of blood cancer called Acute Leukemia. Acute leukemia is an illness where the bone marrow makes too many white blood cells that are abnormal. This study is divided into two parts: first, to figure out the best dose of the new medicine, and second, to check if it’s safe at that dose. For up to 2 years and 10 months, researchers will follow participants closely and check for any changes in their health. They will look at the number of participants who experience bad side effects, how much of the drug is in their bodies, and how the disease is responding to the new medicine. The main goal is to find a dose of the drug that’s both safe and can possibly help patients with acute leukemia.

    • JNJ-75276617- new potential treatment for Acute myeloid leukemia
  • Testing a new drug for advanced prostate cancer

    This trial compares a new drug called AZD5305 with a placebo in men who have a specific kind of prostate cancer that has not responded to usual treatment methods. It’s a large trial, with around 1800 participants, and the main aim is to see whether the new treatment can help slow down the disease for longer than current treatments. Participants will be assigned to two different groups, and they will not know whether they’re receiving the real drug or the placebo. Their health will be monitored closely, with regular scans to check the progress of the cancer. The trial will also look at any side effects of the treatment and how it affects the patients’ ability to do their daily activities.

    • Enzalutamide/Xtandi
    • Darolutamide/Nubequa
    • Abiraterone Acetate/Zytiga
    • Saruparib
  • Stomach cancer treatment comparison: trastuzumab deruxtecan vs. ramucirumab & paclitaxel

    This is a thorough comparison study to measure the effectiveness and safety of two treatment paths. It’s designed for individuals who have experienced progression regarding a stomach (gastric) cancer, or cancer of the gastro-esophageal junction (GEJ). The study focuses on those with HER2-positive gastric or GEJ who have previously undergone a trastuzumab-containing regime but have not received further systemic therapy.The research compares the use of trastuzumab deruxtecan, a potent anti-cancer agent, and the combined use of ramucirumab and paclitaxel. The study’s primary goal is to evaluate the overall survival rate, while secondary aims involve examining progression-free survival, response duration, disease control, safety, pharmacokinetics, and immunogenicity.In the study, participants are fairly and randomly assigned to receive one of two treatments. This is crucial in understanding the superiority and safety of these treatment paths, and this knowledge may inform future approaches to treating these types of cancer.

    • Ramucirumab
    • Trastuzumab deruxtecan
    • Paclitaxel
  • Comparison of different drug combinations in the treatment of relapsed mantle cell lymphoma

    In this trial, Glofitamab will be tested on patients with mantle cell lymphoma that has either recurred or not responded to prior therapy. The effectiveness of this medicine will be compared to alternative treatments suggested by physicians, such as a rituximab and bendamustine mix or a combination of lenalidomide and rituximab. Participants will be asked questions about their physical and emotional well-being, ability to handle day-to-day responsibilities, cognitive function, social lifestyle, symptoms like tiredness, vomiting, pain, etc., and overall health condition and life quality.

    • Tocilizumab
    • Obinutuzumab
    • Glofitamab
    • Bendamustine
    • Lenalidomide
    • Rituximab
  • Investigating new treatment method for specific head and neck squamous cell carcinoma

    This clinical trial is focused on evaluating the safety and efficacy of a new treatment for patients with a specific type of head and neck cancer caused by Human Papilloma Virus 16 (HPV16) and characterized by the presence of the PD-L1 protein. The treatment involves a combination of a novel drug, BNT113, and a known drug, pembrolizumab. The primary objective is to determine whether this combination is more effective than pembrolizumab alone in assisting the body’s immune system in fighting the cancer. The trial is divided into two parts. In the initial phase, the focus is on assessing the safety of the new drug combination. Subsequently, in the second phase, patients will be randomly assigned to receive either the new combination or pembrolizumab alone. The trial aims to compare the outcomes of the two groups, evaluating tumor response (whether tumors shrink, remain the same, or grow) and monitoring any potential side effects resulting from the treatment.

    • BNT113
    • Pembrolizumab
  • Study relating to new treatment for ovarian cancer

    This is a study for patients who have ovarian, fallopian tube, or primary peritoneal cancer that has resisted platinum-based treatments. The main goal is to see how well two drugs, Nemvaleukin Alfa and Pembrolizumab, work together compared to other chemotherapy treatments that the doctor chooses. Patients will be picked randomly by a computer to receive either the two-drug combo, one of the two drugs alone, or other chemo drugs, such as doxorubicin, paclitaxel, topotecan, or gemcitabine. This study is open, which means everyone will know which treatment is being given.

    • Nemvaleukin
    • Pegylated Liposomal Doxorubicin
    • Pembrolizumab
    • topotecan
    • Gemcitabine
    • Paclitaxel

See more clinical trials in other cities in United Kingdom:

.